Investigations of cellular immunity in juvenile idiopathic arthritis

Area of Science:

• Rheumatology
• Immunology
• Pediatrics

Background:

• Juvenile idiopathic arthritis (JIA) is a chronic arthritis affecting approximately 1 in 1000 children.
• While it can occur at any age, it is rare in infants under six months.
• An estimated 300,000 children in the U.S. have been diagnosed with JIA.

Purpose of the Study:

• To assess immunological investigations in patients with JIA.
• To explore the immune system's implications in the development and progression of JIA.
• To identify potential new treatment pathways through understanding immune responses.

Main Methods:

• Review of specifically targeted proteins: citrullinated peptide antibodies.
• Analysis of non-specifically targeted proteins: heat-shock proteins (anti-HSP60, -65, -70 antibodies), CLEC16A, inflammasomes, and phagocyte-derived S100.
• Discussion of interleukins (IL-1, IL-6, IL-10, IL-17, IL-18), innate immunity (macrophage activation syndrome, NK cells, complement, immune complexes), and therapeutic targets (monoclonal antibodies, JAK inhibitors, IVIG).

Main Results:

• The study outlines various immunological markers and pathways implicated in JIA.
• It details specific and non-specific protein targets, cytokine profiles, and innate immune system involvement.
• Potential therapeutic targets, including monoclonal antibodies and JAK inhibitors, are identified.

Conclusions:

• Comprehensive understanding of immunological investigations is crucial for advancing JIA treatment.
• Targeting specific immune system components offers promising avenues for novel therapeutic strategies.
• Further research into these immunological aspects can lead to improved management of JIA.